{"product_id":"castlebiosciences-five-forces-analysis","title":"Castle Biosciences Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Strategic Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eCastle Biosciences faces intense buyer scrutiny and evolving substitute diagnostics, while moderate supplier leverage and regulatory hurdles shape its margins; emerging entrants and partnerships could shift competitive dynamics quickly. This brief snapshot only scratches the surface — unlock the full Porter's Five Forces Analysis to explore Castle Biosciences’s competitive dynamics, market pressures, and strategic advantages in detail.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Laboratory Equipment Manufacturers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCastle Biosciences depends on a few global firms for high-end sequencers and diagnostic hardware, giving suppliers strong leverage; switching costs exceed $2–5M per lab install and 6–12 months of validation.\u003c\/p\u003e\n\u003cp\u003eEquipment needs proprietary software and certified maintenance, raising downtime risk; in 2024, diagnostics-capex suppliers reported 20–30% gross margins, underscoring pricing power. Castle must sustain vendor ties to keep access to new genomic assays and uninterrupted operations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReagent and Consumable Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCastle Biosciences depends on specialized reagents and kits for DecisionDx tests; in 2024 reagent spend was roughly 18% of lab costs, per company filings, so supplier moves matter. Some reagents are generic, but platform‑specific items create dependency on a few manufacturers, raising switching costs and risk. A supply disruption or price rise of 10–15% could shave several percentage points off gross margin and reduce throughput. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBioinformatics and Data Storage Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCastle Biosciences relies on major cloud providers (AWS, Google Cloud, Microsoft Azure) and niche bioinformatics vendors to store\/process genomic data; the three cloud firms held about 66% of global IaaS\/PaaS market in 2024, giving them pricing leverage and tighter SLAs.\u003c\/p\u003e\n\u003cp\u003eSwitching bioinformatics tools incurs costly validation and regulatory re‑submission; typical clinical pipeline revalidation can take 6–12 months and cost $0.5–2M, so supplier concentration raises Castle’s supplier bargaining power.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLogistics and Cold-Chain Transportation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe integrity of tissue samples demands specialized cold-chain carriers; in 2024 about 60% of clinical-sample transport in the US used validated cold-chain logistics, narrowing Castle Biosciences’ supplier pool and raising switching costs.\u003c\/p\u003e\n\u003cp\u003eRegulatory rules (UN3373, FDA guidance) and CLIA-driven handling reduce viable partners; a single major logistics failure can cost millions—sample loss often means lost test revenue (~$1,000–$3,500 per oncology test) and reputational harm.\u003c\/p\u003e\n\u003cp\u003eWhat this hides: concentration risk if one carrier serves \u0026gt;30% of shipments.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh reliability required—few qualified carriers\u003c\/li\u003e\n\u003cli\u003eRegulatory constraints raise switching costs\u003c\/li\u003e\n\u003cli\u003eSample loss = $1k–$3.5k revenue per test\u003c\/li\u003e\n\u003cli\u003eCarrier concentration risk (\u0026gt;30% exposure)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Lab Personnel and Talent\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe limited supply of lab technicians, molecular biologists, and bioinformaticians gives suppliers strong bargaining power; biotech hiring competition drove US median biotech scientist pay to about $110,000 in 2024 and reported turnover above 18% in 2023.\u003c\/p\u003e\n\u003cp\u003eCastle Biosciences must match market pay, benefits, and training to retain CLIA-certified lab staff; failure raises assay downtime risk and increases recruiter fees (often 20–30% of first-year salary).\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh demand: median pay ~$110,000 (2024)\u003c\/li\u003e\n\u003cli\u003eTurnover: \u0026gt;18% (2023)\u003c\/li\u003e\n\u003cli\u003eRecruiter fees: 20–30% of salary\u003c\/li\u003e\n\u003cli\u003eRisk: assay downtime, quality loss\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupplier Concentration Threatens Margins: Cloud, Reagents \u0026amp; Validation Costs Bite\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuppliers exert strong leverage: high‑end sequencers, proprietary reagents, cloud\/IaaS (66% market share in 2024) and cold‑chain carriers concentrate costs and risk; switching costs: $0.5–5M and 6–12 months validation; reagent spend ~18% of lab costs (2024); a 10–15% input price rise could cut several percentage points of gross margin.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003e2024\/2023 Metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCloud share\u003c\/td\u003e\n\u003ctd\u003e66% IaaS\/PaaS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReagent spend\u003c\/td\u003e\n\u003ctd\u003e~18% lab costs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eValidation cost\/time\u003c\/td\u003e\n\u003ctd\u003e$0.5–5M, 6–12 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrice shock impact\u003c\/td\u003e\n\u003ctd\u003e10–15% → several pts GM\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored exclusively for Castle Biosciences, this Porter's Five Forces overview uncovers competitive drivers, buyer and supplier power, substitution risks, and entry barriers shaping its pricing, margins, and strategic positioning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-sheet Porter's Five Forces for Castle Biosciences—quickly spot competitive pressures, tailor force levels to new data, and drop clean visuals into decks for rapid strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedicare and Government Payers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMedicare accounts for roughly 30–40% of Castle Biosciences' revenue mix for diagnostics like DecisionDx-Melanoma, given the older-skewing melanoma cohort; that concentration makes Medicare a single large payer with outsized influence.  \n\u003c\/p\u003e\n\u003cp\u003eAs the government sets reimbursement rates and coverage policies, changes in local coverage determinations or Medicare pricing—e.g., a 10% cut—could reduce diagnostic margin and revenue materially, risking slower market access and commercial uptake.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercial Insurance Companies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCommercial insurers wield strong leverage, demanding robust clinical utility evidence before favorable coverage for Castle Biosciences’ genomic tests; in 2024 about 62% of major private plans required explicit evidence of cost savings for molecular diagnostics.\u003c\/p\u003e\n\u003cp\u003eThey negotiate price aggressively and use prior authorization to curb use, adding months-long approval timelines that lower test uptake and revenue predictability.\u003c\/p\u003e\n\u003cp\u003eCastle must keep funding outcome studies—its 2023 R\u0026amp;D spend was $62.8M—to show tests cut total cost of care and secure broader, higher-priced coverage.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDermatologists and Oncology Specialists\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDermatologists and oncology specialists, while not the payers, directly decide which Castle Biosciences tests to order, giving them high bargaining power to switch to rivals or standard pathology; Castle reported 2024 revenue of $369.6M and must protect clinician share to sustain growth. Clinicians value validated clinical utility—Castle’s DecisionDx-Melanoma and myPath Melanoma cite peer-reviewed outcome links—so maintaining trust, fast turnaround (median 5–7 days), and clear actionability is critical to clinician loyalty.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegrated Delivery Networks and Large Hospitals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cplarge health systems and integrated delivery networks centralize purchasing can demand volume discounts or data reporting squeezing margins for castle biosciences in the top us accounted of hospital admissions concentrating buying power. securing approved-lab status a major idn typically drives multi-year contracts raise regional test volumes by within months.\u003e\n\u003cp class=\"lst_crct\"\u003e\n\u003c\/p\u003e\u003cli\u003eTop 25 US systems ≈30% admissions (2024)\u003c\/li\u003e\n\u003cli\u003eApproved-lab status → +20–40% test volume\u003c\/li\u003e\n\u003cli\u003eIDNs demand volume discounts, data integration\u003c\/li\u003e\n\u003cli\u003eLoss of access risks significant regional revenue drop\u003c\/li\u003e\n\u003c\/plarge\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Advocacy Groups and Self-Pay Patients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cppatients are choosing tests more and pushing payers for coverage patient advocacy groups have swayed cms private insurers on genetic testing raising end-user leverage against castle biosciences.\u003e\n\u003cpcastle runs financial assistance and a patient access program covering up to for eligible patients which reduces price pushback but doesn eliminate influence as price-transparency rules increased shopping diagnostics.\u003e\n\u003cpthe trend matters: surveys show of patients compare test costs online and would decline non-covered tests due to cost so end-user power is rising despite assistance.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e62% compare diagnostic costs online (2024 survey)\u003c\/li\u003e\n\u003cli\u003e28% decline non-covered tests due to cost\u003c\/li\u003e\n\u003cli\u003eCastle offers patient assistance up to 100% for eligible cases\u003c\/li\u003e\n\u003cli\u003eAdvocacy groups influence coverage policy and reimbursement\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthe\u003e\u003c\/pcastle\u003e\u003c\/ppatients\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBuyers Dictate Terms: Payers, Systems \u0026amp; Patients Squeeze Margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCustomers hold high bargaining power: Medicare (30–40% revenue) and major private insurers (62% require cost‑saving evidence) set coverage and pricing that can cut margins; dermatologists\/oncologists control ordering and can switch tests; top 25 US health systems (~30% admissions) demand discounts and integration; patients increasingly shop (62% compare costs) and pressure payers.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBuyer\u003c\/th\u003e\n\u003cth\u003eKey stat (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare\u003c\/td\u003e\n\u003ctd\u003e30–40% revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrivate insurers\u003c\/td\u003e\n\u003ctd\u003e62% require cost‑savings evidence\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop 25 health systems\u003c\/td\u003e\n\u003ctd\u003e~30% admissions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients\u003c\/td\u003e\n\u003ctd\u003e62% compare costs; 28% decline non‑covered\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eCastle Biosciences Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Castle Biosciences Porter’s Five Forces analysis you'll receive immediately after purchase—no placeholders and fully formatted for immediate use.\u003c\/p\u003e\n\u003cp\u003eIt contains the complete assessment of supplier and buyer power, competitive rivalry, threat of substitutes, and barriers to entry, identical to the downloadable document delivered after payment.\u003c\/p\u003e\n\u003cp\u003eYou're viewing the final, professionally written file; once you buy, you’ll get instant access to this same ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56747542118777,"sku":"castlebiosciences-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/castlebiosciences-five-forces-analysis.png?v=1772199659","url":"https:\/\/growthsharematrix.com\/products\/castlebiosciences-five-forces-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}